Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | ACACB | O00763 | 1/20 | 0.43 |
| ▸ | TARBP2 | Q15633 | 1/20 | 0.43 |
| ▸ | VCP | P55072 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL852513 | 0.90 | GAA (0.50) | SMN1; SMN2FFAR1NPC1RAB9AGAA | |
| SCHEMBL28747451 | 0.83 | VCP (0.46) | SMN1; SMN2MAPTCYP1A2FFAR1NPC1 | |
| SCHEMBL9935172 | 0.81 | CA12 (0.50) | SMN1; SMN2MAPTNPC1RAB9AGAA | |
| SCHEMBL9934062 | 0.81 | FFAR1 (0.59) | SMN1; SMN2MAPTL3MBTL1FFAR1NPC1 | |
| SCHEMBL788820 | 0.80 | APP (0.49) | FFAR1GAAACACBALDH1A1 | |
| SCHEMBL2300644 | 0.80 | ACACB (0.44) | MAPTL3MBTL1FFAR1NPC1RAB9A | |
| SCHEMBL2433672 | 0.80 | APP (0.45) | SMN1; SMN2MAPTCYP1A2FFAR1NPC1 | |
| SCHEMBL852379 | 0.80 | L3MBTL1 (0.44) | SMN1; SMN2MAPTL3MBTL1RAB9AKDM4E | |
| SCHEMBL11544791 | 0.80 | ALDH1A1 (0.53) | L3MBTL1NPC1ACACBALDH1A1 | |
| SCHEMBL1977638 | 0.80 | POLB (0.44) | SMN1; SMN2MAPTL3MBTL1CYP1A2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260028554-A1 | FRAGRANCE AND FLAVOR COMPOSITIONS COMPRISING AROMATIC DERIVATIVES | OSMO LABS PBC (US) | 2026-01-29 | — | — | US | disclosed |
| US-8003806-B2 | Integrin antagonists useful as anticancer agents | OSI Pharmaceuticals, LLC (US) | 2011-08-23 | — | — | US | disclosed |
| EP-1828144-A2 | INTEGRIN ANTAGONISTS USEFUL AS ANTICANCER AGENTS | OSI Pharmaceuticals, Inc. (US) | 2007-09-05 | — | — | EP | disclosed |
| US-20060116383-A1 | Integrin antagonists useful as anticancer agents | ALCATEL LUCENT (FR) | 2006-06-01 | — | — | US | disclosed |
| WO-2006053342-A2 | INTEGRIN ANTAGONISTS USEFUL AS ANTICANCER AGENTS | OSI PHARMACEUTICALS, INC. (US) | 2006-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116383-A1 | Integrin antagonists useful as anticancer agents | ITGB5, ITGA5, ITGB1 | SMN1; SMN2 2159/4885MAPT 4745/4885L3MBTL1 1292/4885 |
| US-20260028554-A1 | FRAGRANCE AND FLAVOR COMPOSITIONS COMPRISING AROMATIC DERIVATIVES | TAS2R42, TAS2R4, TAS2R41 | SMN1; SMN2 3843/4885MAPT 4029/4885L3MBTL1 2468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.